FDA would reclassify cranial electrotherapy stimulators (CES) into two separate classes, placing those intended to treat insomnia and anxiety into class II, with special controls to mitigate risks, and those designed to treat depression into class III requiring a PMA, under a proposed order
released Jan. 21.